Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity
Dateline City:
BOSTON
Company Provides Updates on Near-Term Opportunities and Immuno-Oncology Strategy
Announced Sale of Consumer Care Business to Bayer AG for $14.2 Billion; Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease
MK-3475 BLA Accepted for Priority Review by FDA; Company Announced Plans to File in EU in 2014
Provided Updates on Clinical Development Programs for Oncology, ...
Source: Merck.com - Corporate News - May 6, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma
Dateline City:
BOSTON
Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with Ipilimumab
Advancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma, Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head & Neck and Bladder Cancers
Data from Studies in Three Different Cancer Types to be presented at 2014 ASCO Annual Meeting
Initiating Phase 1...
Source: Merck.com - Corporate News - May 6, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis
Dateline City:
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Endocyte, Inc. (NASDAQ:ECYT), today announced that the Data Safety
Monitoring Board (DSMB) of the PROCEED trial has completed a
pre-specified, interim futility analysis and the DSMB recommended that
the trial be stopped because vintafolide did not demonstrate efficacy on
the pre-specified outcome of Progression-Free Survival (PFS) in p...
Source: Merck.com - Corporate News - May 2, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck to Hold Investor Briefing at Boston Research Facility
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold an Investor Briefing on Tuesday, May 6, 2014 starting at 9:00
a.m. EDT at its research facility in Boston, MA. During the event,
members of Merck's senior management will detail the company's research
strategy, showcase candidates from the research and development pipeline
and provide a business update.
Language:
English ...
Source: Merck.com - Corporate News - April 28, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck and Award-Winning Actress S. Epatha Merkerson Challenge Americans with Type 2 Diabetes to Get to Their Goals
Dateline City:
WHITEHOUSE STATION, N.J.
Stage and Screen Star Shines a Spotlight on Better Blood Sugar Management With America’s Diabetes Challenge: Get to Your Goals Program
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy and Golden Globe-winning actress S. Epatha Merkerson on America’s Diabetes Challenge: Get to Your Goals, an educational program intended to encourage people with type 2 diabetes to achieve better control of their blood sugar...
Source: Merck.com - Corporate News - April 23, 2014 Category: Pharmaceuticals Tags: Corporate News Source Type: news
FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
Dateline City:
WHITEHOUSE STATION, N.J.
RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for
Sublingual Use (12 Amb a 1-U)...
Source: Merck.com - Corporate News - April 17, 2014 Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults
Dateline City:
WHITEHOUSE STATION, N.J.
GRASTEK is the Only FDA Approved Sublingual Allergy Immunotherapy Tablet Indicated for Children as Young as 5 Years of Age
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved GRASTEK® (Timothy Grass Pollen Allergen Extract)
Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)].
...
Source: Merck.com - Corporate News - April 14, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
Dateline City:
WHITEHOUSE STATION, N.J.
Clinical Findings Support Initiation of C-EDGE Phase 3 Program
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced interim results from the ongoing C-WORTHy study,
a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of
an all-oral, once-daily regimen combining MK-5172, an investigational
hepatitis C virus (HCV) NS3/4A protease inhibitor,...
Source: Merck.com - Corporate News - April 11, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth
Dateline City:
WHITEHOUSE STATION, N.J.
Post-partum Hemorrhage Is Leading Cause of Mothers Dying
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Ferring Pharmaceuticals today announced their collaboration with the
World Health Organization (WHO) to advance a new, proprietary
formulation of carbetocin, used to prevent excessive bleeding
(post-partum hemorrhage) in women after childbirth, that is designed t...
Source: Merck.com - Corporate News - April 4, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the appointment of Robert M. Davis, 47, as executive
vice president and chief financial officer, effective April 23, 2014.
Davis, who will also oversee corporate strategy and corporate business
development, will succeed Peter N. Kellogg, 58.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - March 27, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its first-quarter 2014 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Tuesday, April
29. During the call, company executives will provide an overview of
Merck’s performance for the quarter.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - March 20, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
CHMP Issues Positive Opinion for Tablet Formulation of Merck’s NOXAFIL® (posaconazole)
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of a new, investigational tablet
formulation of NOXAFIL® (posaconazole).
Language:
English
Contact:
...
Source: Merck.com - Corporate News - February 28, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Announces Second-Quarter 2014 Dividend
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the Board of Directors has declared a quarterly
dividend of $0.44 per share of the company’s common stock for the second
quarter of 2014. Payment will be made on April 7, 2014, to stockholders
of record at the close of business on March 17, 2014.
About Merck
Language:
English
Cont...
Source: Merck.com - Corporate News - February 25, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck to Participate in the Citi 2014 Healthcare Conference
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Dr. Roger M. Perlmutter, president, Merck Research
Laboratories, is scheduled to speak at the Citi 2014 Healthcare
Conference in New York City on February 24, 2014 at 8:50 a.m. EST.
Investors, analysts, members of the media and the general public are
invited to join a live webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home...
Source: Merck.com - Corporate News - February 20, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner)
Dateline City:
SUMMIT, N.J.
First Chewable Tablet Approved for Fleas and Ticks in Dogs Effective for 12 Weeks (8 Weeks for Rhipicephalus sanguineus Ticks)
SUMMIT, N.J.--(BUSINESS WIRE)--MSD Animal Health, known as Merck Animal Health in the United States and
Canada, announced today that following a positive opinion from the
Committee for Medicinal Products for Veterinary Use (CVMP), the European
Commission has granted marketing authorization for the veterinary
medi...
Source: Merck.com - Corporate News - February 17, 2014 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News Source Type: news
